Astellas Pharma Inc: Neoplasm Metastasis trials
The registry lists 15 Neoplasm Metastasis studies with Astellas Pharma Inc as lead sponsor. 4 are open to participants now and 3 have results posted.
Phase 1 11Phase 2 2Phase 3 1Phase 4 1(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- A Study to Find a Suitable Dose of ASP5834 in Adults With Solid TumorsRecruitingNCT07094204Phase 1
- A Study of ASP1002 in Adults for Treatment of Solid TumorsRecruitingNCT05719558Phase 1
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingNCT05382559Phase 1
- A Safety and Dose-finding Study of PRL-02 Depot in Men With Advanced Prostate CancerRecruitingNCT04729114Phase 1
- A Study of Enzalutamide Re-treatment in Metastatic Castration-resistant Prostate Cancer After Docetaxel and/or Cabazitaxel TreatmentTerminatedNCT02441517Phase 4Results posted
- A Study to Assess the Benefit of Treatment Beyond Progression With Enzalutamide in Men Who Are Starting Treatment With Docetaxel After Worsening of Their Prostate Cancer When Taking Enzalutamide AloneCompletedNCT02288247Phase 3Results posted
- A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate CancerCompletedNCT01288911Phase 2Results posted
- A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid TumorsWithdrawnNCT06681870Phase 1
- A Study of ASP2074 in Adults With Solid TumorsTerminatedNCT05646797Phase 1
- A Study of an Intratumoral Oncolytic Virus in Patients With Advanced Metastatic Solid TumorsCompletedNCT03954067Phase 1
- Study of ASP8374, an Immune Checkpoint Inhibitor, in Japanese Patients With Advanced Solid TumorsCompletedNCT03945253Phase 1
- A Study of YM155 Plus Docetaxel as First-Line Treatment in Subjects With HER2 Negative Metastatic Breast CancerCompletedNCT01038804Phase 2
- Study of Intermittent OSI-906 DosingCompletedNCT00514306Phase 1
- Study of Continuous OSI-906 DosingCompletedNCT00514007Phase 1
- Phase 1 Study of OSI-930 in Cancer PatientsCompletedNCT00513851Phase 1